"Once the FDA approve lecanemab, it will be up to the UK medical regulators to make their call. I trust that they will make the right decision," said Professor Robert Howard (UCL Psychiatry) who highlighted the possible life-threatening side effects for the new dementia drug.
Read: Mail Online, More: Daily Express, Sun